Publications by authors named "J P de Filippi"

Pt nanoparticles (diameter <3 nm), generated by metal vapor synthesis and supported on a high surface area carbon, were used to catalyze the aerobic oxidation of ethylene glycol to glycolic acid (GA) in water under neutral and basic reaction conditions. Controlled heat treatment of the catalyst under a nitrogen atmosphere brought about the formation of a morphologically well-defined catalyst. A combination of atomic resolution electron microscopy, CO stripping voltammetry, and XPS analyses conducted on as-synthesized and heat-treated catalysts demonstrated the crucial role of the nanoparticles' morphology on the stabilization of catalytically highly active Pt-OH surface species, which were key species for the Pt-catalyzed oxidation of the alcohol to the carbonyl functionality.

View Article and Find Full Text PDF

Background: Tillaux-Chaput fractures (TCFs) consist of fractures of the anterolateral distal tibia. They rarely occur in isolation in adults. When TCFs are missed, there is a risk of chronic pain, instability, and ankle osteoarthritis.

View Article and Find Full Text PDF

More than two decades ago, the advent of Nanotechnology has marked the onset of a new and critical field in science and technology, highlighting the importance of multidisciplinary approaches to assess and model the potential human hazard of newly developed advanced materials in the nanoscale, the nanomaterials (NMs). Nanotechnology is, by definition, a multidisciplinary field, that integrates knowledge and techniques from physics, chemistry, biology, materials science, and engineering to manipulate matter at the nanoscale, defined as anything comprised between 1 and 100 nm. The emergence of nanotechnology has undoubtedly led to significant innovations in many fields, from medical diagnostics and targeted drug delivery systems to advanced materials and energy solutions.

View Article and Find Full Text PDF
Article Synopsis
  • Biosimilars like CT-P17 offer cost-effective treatment options for patients with inflammatory bowel diseases (IBD) and chronic inflammatory rheumatic diseases (CIRD), but patient beliefs about these treatments can impact their adherence to switching.
  • This study involved 232 adult patients who transitioned to CT-P17 from either a low-concentration biosimilar or the reference adalimumab to gauge their treatment satisfaction and experiences over three months.
  • Results showed that satisfaction remained stable overall, but significantly more patients switching from a low-concentration biosimilar reported increased satisfaction compared to those switching from the reference product.
View Article and Find Full Text PDF